These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38155275)

  • 1. Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs.
    Martínez-Domínguez SJ; García-Mateo S; Sainz-Arnal P; Martínez-García J; Gallego-Llera B; Lozano-Limones MJ; Hidalgo S; Gargallo-Puyuelo CJ; Latre-Santos M; Nocito-Colon MML; Martínez-Lostao L; Refaie E; Arroyo-Villarino MT; Del Rio-Nechaevsky M; Ramirez-Labrada A; Pardo J; Gomollón F; Baptista PM
    Sci Rep; 2023 Dec; 13(1):23061. PubMed ID: 38155275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
    Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
    Front Immunol; 2022; 13():920333. PubMed ID: 35865529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM
    Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
    J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.
    Dai C; Dong ZY; Wang YN; Huang YH; Jiang M
    Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
    Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
    J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
    Wong SY; Wellens J; Helmus D; Marlow L; Brann S; Martinez Pazos V; Weinberg A; Moran HR; McGregor C; Vermeire S; Watanabe K; Kamikozuru K; Ahuja V; Vermani S; Lindsay JO; Kingston A; Dutta U; Kaur H; Silverberg MS; Milgrom R; Chien Ng S; Mak JWY; Cadwell K; Thompson C; Colombel JF; Satsangi J;
    Inflamm Bowel Dis; 2023 Nov; 29(11):1693-1705. PubMed ID: 37354560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
    Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
    Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.
    Martin-Arranz MD; García-Ramírez L; Hernandez-Perez M; Montero Vega D; Martín-Arranz E; Sánchez-Azofra M; Poza Cordon J; Rueda Garcia JL; Noci Belda J; Verges Martínez-Meco T; Blanco San Miguel P; Suarez Ferrer C
    Sci Rep; 2023 Apr; 13(1):7044. PubMed ID: 37120662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
    Woelfel S; Dütschler J; König M; Dulovic A; Graf N; Junker D; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Koller S; Wyss J; Krupka N; Oberholzer M; Frei N; Geissler N; Schaub P; ; Albrich WC; Friedrich M; Schneiderhan-Marra N; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Oct; 58(7):678-691. PubMed ID: 37571863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
    Motwani KK; Hashash JG; Farraye FA; Kappelman MD; Weaver KN; Zhang X; Long MD; Cross RK
    J Crohns Colitis; 2023 Nov; 17(10):1681-1688. PubMed ID: 37232444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.
    Algaba A; Romero S; Granja A; Garza D; Aller M; Barrero S; Guerra I; Gil M; Pizarro N; Ruiz P; Prieto S; Hernández B; Pou A; Bermejo F
    Gastroenterol Hepatol; 2023 Jan; 46(1):48-53. PubMed ID: 35605819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
    Kastl AJ; Weaver KN; Zhang X; Strople JA; Adler J; Dubinsky MC; Bousvaros A; Watkins R; Dai X; Chen W; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Chun KY; Zikry M; Fernando M; Bastidas M; Hernandez CG; Craig RG; Boccieri ME; Firestine A; Long MD; Kappelman MD
    Am J Gastroenterol; 2023 Jan; 118(1):129-137. PubMed ID: 36114773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.